Fluad

Fluad is a specialized influenza vaccine formulated to protect against multiple strains of the flu virus, including two influenza A strains and one influenza B strain. The strains included in the current formulation are A/Victoria/4897/2022 (H1N1)pdm09-like strain, A/Croatia/10136RV/2023 (H3N2)-like strain, and B/Austria/1359417/2021-like strain. These strains are selected annually based on guidance from global health authorities to match those most likely to circulate during the flu season, ensuring the vaccine provides effective protection against prevalent influenza viruses.
Fluad is produced using advanced manufacturing processes that include an adjuvant, which helps enhance the immune response to the vaccine. This adjuvant allows the body to generate a stronger and longer-lasting response, increasing the effectiveness of the vaccine, particularly in populations that may have weaker immune reactions, such as older adults. The vaccine is administered as an injection, usually into the upper arm muscle, under the supervision of trained healthcare professionals to ensure proper delivery and monitoring.
The purpose of Fluad is to stimulate the body’s immune system to recognize the included virus strains and develop protective antibodies. This process helps reduce the risk of contracting influenza and lowers the severity of illness if infection occurs. Annual vaccination is recommended due to the evolving nature of influenza viruses, which can change from year to year.
Individuals receiving Fluad may experience mild and temporary reactions, such as soreness at the injection site, fatigue, or low-grade fever. Regular vaccination with Fluad contributes to broader public health efforts to prevent seasonal influenza, reduce hospitalizations, and protect vulnerable populations. By targeting multiple influenza strains with an enhanced immune response, Fluad serves as an important tool for seasonal influenza prevention and maintaining overall community health.